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Renal hemodynamic effects of somatostatin are not related to Somatostatin inhibits hormone secretion, which repre-
inhibition of endogenous insulin release. sents the rationale for the treatment of acromegaly, insu-
Background. Somatostatin inhibits endocrine and exocrine linomas or prolactinomas. In addition, somatostatin ex-secretions and exerts renal vasoconstriction. The mechanism
erts potent vasoactive actions that are therapeutically usedunderlying somatostatin’s vascular effects is unknown. Since
for upper gastrointestinal bleeding and surgical condi-insulin can cause vasodilation, we hypothesized that removal
of basal insulin release by somatostatin may contribute to so- tions of the pancreas [1–4]. Furthermore, it has been
matostatin-induced renal vasoconstriction. demonstrated that somatostatin may exert vasoconstric-
Methods. The study was conducted in different protocols tion in the kidney [5–8]. In renal diseases associated withcomprising forty-six healthy male volunteers. Randomized stud-
glomerular hyperfiltration, namely acromegaly and earlyies were performed to compare the effects of somatostatin alone
stage diabetic nephropathy, somatostatin reduced renal(0.1g/kg/min) to the effects of somatostatin low dose insulin
(0.1 mU/kg/min), the effects of somatostatin low dose insulin hyperfiltration [9–11].
to the effects of somatostatin  high dose insulin (1.5 mU/kg/ The exact mechanism underlying somatostatin-induced
min), and the effects of insulin (1.5 mU/kg/min)  somato-
vasoconstriction is unknown, yet endothelium dependentstatin. Renal plasma flow (RPF) and glomerular filtration rate
and independent mechanisms have been suggested can-(GFR) were measured with the para-aminohippurate (PAH)
and the inulin clearance technique, respectively. Blood pres- didates. As insulin exerts vasodilation via a nitric oxide-
sure and pulse rate were measured non-invasively. dependent mechanism [12, 13], we hypothesized that
Results. Somatostatin alone decreased GFR (14  6%, removal of basal (fasting) insulin by somatostatin mayP  0.001) and RPF (16  7%, P  0.001) whereas systemic
contribute to the vasoconstrictive actions.hemodynamics were unchanged. Preceding or concomitant in-
The aim of the present study was to determine whetherfusion of insulin at high doses (insulin plasma concentration
of 127  25 or 144  17 U/mL) but not co-infusion with low the vasoconstrictor activity of somatostatin is caused by
dose insulin (insulin plasma concentration of 11  3 U/mL) the removal of basal insulin release. To test this hypothe-
mitigated or reversed the vasoconstrictive actions of somato-
sis, somatostatin was administered in the presence ofstatin on GFR and RPF.
different insulin concentrations under euglycemic condi-Conclusions. Somatostatin induces marked renal vasocon-
striction and exogenous restoration of fasting insulin concen- tions. In control experiments somatostatin also was in-
trations does not influence the renal vascular effects. Therefore, fused after high circulating concentration of insulin had
it is unlikely that somatostatin-induced vasoconstriction is due been established. Systemic hemodynamics were assessedto removal of basal insulin. Plasma insulin concentrations in
by non-invasive techniques, glomerular filtration ratethe high postprandial range can reverse somatostatin-induced
(GFR) and renal plasma flow were studied using therenal vasoconstriction, suggesting functional antagonism.
para-aminohippurate (PAH) and the inulin clearance
technique, respectively.
METHODS
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Forty-six healthy male subjects (age range 20 to 33Received for publication April 12, 2001
years) were included in this study. All subjects signed aand in revised form November 15, 2001
Accepted for publication December 17, 2001 written informed consent and were drug-free during the
two weeks prior to health screening and throughout the 2002 by the International Society of Nephrology
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study period. The study was approved by the Ethics utes. Blood pressure was measured in 15-minute inter-
Committee of the University of Vienna and conformed vals during the study period. Pulse rate and a real time
with the principles outlined in the Declaration of Hel- ECG were monitored continuously.
sinki including current revisions and the GCP guidelines.
MethodsAll subjects underwent a complete health examination
(including physical examination, ECG and laboratory Noninvasive systemic hemodynamics. Systolic (SBP),
screening) within 14 days prior to the study day. After diastolic (DBP) and mean arterial pressures (MAP) were
overnight fasting, subjects were admitted to the Depart- measured on the upper arm by an automated oscillome-
ment of Clinical Pharmacology, General Hospital Vi- tric device. Pulse rate was automatically recorded from
enna, where studies were started at 8 to 9 am in a quiet a finger pulse-oxymetric device. A 12-lead ECG was taken
room with an ambient temperature of 22C and with from a standard device (Hewlett Packard CMS patient
complete resuscitation facilities. monitor, Hewlett Packard, Palo Alto, CA, USA).
Renal hemodynamic measurements. The validated pro-Study design
cedure for determination of renal hemodynamics using
The study comprised three different protocols. Proto-
the PAH and inulin clearance techniques without urine
col 1 (N  27) followed a randomized parallel group
collection is described in detail elsewhere [14]. PAHdesign and studied the effects of somatostatin without
plasma concentrations were measured by photometricor with concomitant administration of low doses of insu-
analysis. Inulin plasma concentrations were measuredlin or vehicle control alone over a period of time. In
by a commercially available test (INUTEC; Laevosan,protocol 2 (N  9), a randomized, double-blind cross-
Linz, Austria). Renal perfusion flow (RPF) and glomeru-over design was selected to investigate the effects of
lar filtration rate (GFR) were estimated as the infusiondifferent concentrations of circulating insulin (high dose
clearance of PAH and inulin, respectively. Filtrationor low dose). In protocol 3 (N 10), control experiments
fraction was calculated as FF  GFR/RPF.studied the effects of somatostatin preceded by high-
Hormone levels of growth hormone, glucagon, insulindose insulin. In this additional experiment, hormone lev-
and plasma renin activity were quantified by routineels (growth hormone, glucagon, insulin and plasma renin
laboratory methods at the certified laboratory of theactivity) also were quantified.
Institute of Medical and Chemical Laboratory Diagnos-In order to standardize the sodium intake, subjects
tics, AKH Wien (University of Vienna, Austria).received 2 g sodium chloride for two days prior the trial
Euglycemic insulin clamp. Euglycemic clamps weredays in addition to their normal diet. In addition, subjects
were given a 200 mL water load one hour before the performed according to DeFronzo, Tobin and Andres
study and were encouraged to drink 200 mL/hour during [15]. Each clamp was started with a bolus infusion fol-
the infusion experiments. lowed by a constant infusion rate of insulin of 0.1 mU/
On all study days a resting period of at least 20 minutes kg/min or 1.5 mU/kg/min. Glucose was infused at a vari-
was scheduled in supine position. Thereafter a primed able rate necessary to maintain blood glucose levels in
constant infusion of PAH (8 mg/kg bolus, continuous arterialized venous blood samples between 80 and 120
infusion of 15 mg/min/1.73 m2; Clinalfa, La¨ufelfingen, mg/dL. Glucose concentration was measured with a Beck-
Switzerland) and inulin (37.5 mg/kg bolus, continuous man glucose analyzer (Beckman Glucose Analyzer 2;
infusion of 35 mg /min/1.73 m2; Laevosan, Linz, Austria) Beckman Instruments Inc., Fullerton, CA, USA).
was started. After 45 minutes of infusion, baseline pa-
rameters were obtained and the drugs under study were Statistical analysis
administered for 180 minutes. Somatostatin (Somato- All statistical analyses were done using the Statistica
statin UCB; UCB PHARMA, Vienna, Austria) was in- Software Release 4.5 (Statsoft, Tulsa, OK, USA). Values
fused at a dose of 0.1 g/kg/min, insulin (low dose) at
were expressed as means  SD. Statistical significances0.1 mU/kg/min or insulin at 1.5 mU/kg/min (high dose)
were assessed by repeated measure ANOVA and Wil-and glucose at a variable dose to maintain euglycemia.
coxon matched pairs test. A two-tailed P value 0.05In control experiments the high dose of insulin was in-
was considered the level of significance.fused for one hour alone and thereafter somatostatin
was co-infused.
Blood samples for PAH and inulin clearances and RESULTS
insulin levels were drawn at baseline and thereafter every
Somatostatin and low dose insulin60 minutes. Blood samples to adjust for blood glucose
Systemic and renal hemodynamic parameters wereduring insulin clamps were drawn every five minutes. In
comparable between groups at baseline (data not shown)protocol 3 the concentrations of renin, growth hormone,
glucagon and insulin also were measured every 60 min- and time control experiments demonstrated stable con-
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Table 2. Effects of somatostatin, somatostatin plus low-dose insulin,Table 1. Effects of somatostatin, somatostatin plus low-dose insulin,
or vehicle time control on mean arterial pressure (MAP, mm Hg) or vehicle time control on filtration fraction
and pulse rate (PR, bpm)
Time minutes Somatostatin Somatostatin insulin Vehicle
Somatostatin
Baseline 0.160.02 0.160.02 0.150.03Somatostatin insulin Vehicle
60 0.160.03 0.160.02 0.150.02
120 0.160.03 0.160.02 0.150.02Time minutes MAP PR MAP PR MAP PR
180 0.160.03 0.150.02 0.150.02
Baseline 9211 576 969 627 9011 6710
Results are presented as mean  SD, N  9/group.60 9211 564 915 607 9011 6411
120 918 584 948 597 909 6610
180 8810 574 897 597 928 6612
Results are presented as mean  SD, N  9/group.
Table 3. Insulin levels (U/mL) at baseline and after 180 minutes
Parameter time Insulin level
Somatostatin (N9)
Baseline 7.21.4
180 min 2.30.4a
Somatostatin low dose insulin (N9)
Baseline 6.81.6
180 min 10.82.7b
Vehicle (N9)
Baseline 6.91.7
180 min 7.11.4
Somatostatinhigh dose insulin (N9)
Baseline 6.41
180 min 14817a,c
High dose insulin somatostatin (N10)
Baseline 7.91.7
180 min 12725a
Results are presented as mean  SD.
a P  0.05 vs. baseline
b P  0.05, somatostatin vs. somatostatin  low dose insulin
c P  0.05, somatostatin  high dose vs. somatostatin  low dose insulin
caused renal vasoconstriction in the presence of low dose
insulin and decreased GFR from 145  9 (baseline) to
122  10 mL/min (16%, P  0.001) after 180 minutes
and RPF from 918  124 (baseline) to 803  79 mL/
min (13%, P  0.001) after 180 minutes (Fig. 1). The
effect of somatostatin plus low-dose insulin was compa-
rable to the effect of somatostatin alone. Filtration frac-
tion (FF) remained unchanged by treatment (Table 2). As
expected, somatostatin decreased plasma insulin concen-
trations, which was not seen during infusion of low dose
insulin or during vehicle control experiments (Table 3).
Somatostatin with low- or high-dose insulin
Fig. 1. Changes in glomerular filtration rate (GFR, mL/min) and renal The effects of somatostatin plus low-dose insulin on
plasma flow (RPF, mL/min) during time control (), somatostatin
renal parameters were comparable to those in protocol( ) and somatostatinlow-dose insulin ( ) administration. Data are
presented as % change versus baseline, mean  SD, N  9/group. 1. Again, no effects on MAP or PR were observed (data
not shown), whereas GFR and RPF decreased signifi-
cantly after 180 minutes from 134 12 to 117 8 (13%,
P  0.05), and from 975  103 to 852  94 mL/minditions during the study period (Table 1 and Fig. 1). The
(13%, P  0.0003), respectively (Fig. 2). In contrastdrug under study had no effects on MAP or pulse rate
to infusion of low-dose insulin, the administration of(PR; Table 1). Somatostatin alone reduced GFR from
high-dose insulin prevented the vasoconstrictive effects138  12 mL/min (baseline, mean  SD) to 119  15
of somatostatin on GFR and RPF (P  0.001, each vs.mL/min (14%, P  0.001) after 180 minutes and RPF
low-dose insulin), which remained stable during the ex-from 894  110 mL/min (baseline) to 748  98 mL/min
(16%, P  0.001) after 180 minutes. Somatostatin also periment (136  14 vs. 135  12 mL/min and 921  109
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Fig. 3. Changes in glomerular filtration rate (; GFR, mL/min) and
renal plasma flow (; RPF, mL/min) during high-dose insulin alone,
and after co-administration of somatostatin after 60 minutes. Data are
presented as mean SD, N 10/group, *P 0.05 vs. baseline (0 min).
Fig. 2. Changes in glomerular filtration rate (GFR, mL/min) and renal
plasma flow (RPF, mL/min) during somatostatin  low dose ( ) and
somatostatin  high-dose insulin administration (). Data are pre-
Somatostatin preceded by high-dose insulinsented as % change versus baseline, mean  SD, N  9/group.
High-dose insulin infusion had no effect on GFR,
which was 141  30 mL/min before and 138  26 mL/
Table 4. Effects of somatostatin plus low-dose insulin or min after 60 minutes (P 0.09). RPF also was unchanged
somatostatin plus high-dose insulin on filtration fraction after 60 minutes of high-dose insulin administration
Somatostatin Somatostatin High-dose (790  168 at baseline vs. 803  172 mL/min, P  0.6).
low-dose high-dose insulin After co-administration of somatostatin GFR declinedinsulin insulin somatostatin
to 127  30 mL/min after one hour (10%, P  0.009)Time minutes (N9) (N9) (N10)
and remained stable thereafter until the end of the studyBaseline 0.140.02 0.150.02 0.180.03
60 0.140.02 0.150.02 0.170.02 period (127  27 mL/min, P  0.01 vs. baseline; Fig. 3).
120 0.150.02 0.150.02 0.160.02a The co-infusion of somatostatin with high-dose insulin
180 0.140.02 0.150.02 0.150.03a
had no effect on RPF after one (788 130 mL/min, P
Results are presented as mean  SD.
0.6 vs. baseline) or two hours (826  129 mL/min, P a P  0.05 vs. baseline
0.1 vs. baseline; Fig. 3). The reduction of GFR resulted
in a significant decrease of FF from 0.18 0.03 to 0.16
0.02 after 120 minutes (P  0.007) and to 0.15  0.03vs. 922  97 mL/min, respectively; Fig. 2). There was no
(P  0.003) after 180 minutes (Table 4). MAP and PRchange in FF on the study days (Table 4).
remained unchanged during the experiment (data notInsulin plasma levels are presented in Table 3. Whereas
shown).somatostatin plus low-dose insulin did not affect plasma
Glucose, insulin, growth hormone, glucagon levels andinsulin, somatostatin plus high-dose insulin significantly
plasma renin activity are shown in Table 5. As expected,increased plasma insulin concentrations to values in the
high postprandial range. insulin was significantly increased during infusion and
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Table 5. Blood glucose, insulin, growth hormone, glucagon concentration and plasma renin activity at baseline and during high-dose insulin
and after start of co-administration with somatostatin after 60 minutes
Glucose Insulin Growth hormone Glucagon Plasma renin activity
Time minutes mg/dL lU/mL ng/mL pg/mL ng/mL/h
Baseline 927 7.91.7 0.30.4 749 10.4
60 8018 11933a 0.30.3 5611a 0.70.5
120 9814b 12633a 0.060.04a,b 4610a,b 0.50.4a
180 9114 12725a 0.040.03a,b,c 469a,b 0.40.3a,b,c
Results are presented as mean  SD (N  10).
a P  0.05 vs. baseline
b P  0.05 vs. 60 minutes
c P  0.05 vs. 120 minutes
somatostatin reduced plasma concentrations of growth filtration fraction. Filtration fraction was only affected
when somatostatin was administered after high-dose in-hormone, glucagon and plasma renin activity.
sulin. This was the result of the somewhat smaller amelio-
ration of GFR reduction in this set of experiments and
DISCUSSION does not point toward a specific mechanism. One study
The present study in healthy subjects demonstrates a showed that somatostatin induces contraction of rat aor-
significant decrease in GFR and RPF during somato- tic vascular smooth muscle cells through stimulation of
statin administration, which is in agreement with some specific receptors (SSTR-4) with Ca2 and cyclic adeno-
published data [6, 7, 8, 11], whereas other studies were sise monophosphate (cAMP) as second messengers [23].
not able to demonstrate a significant change in renal The mechanisms involved in somatostatin-induced vaso-
hemodynamics [16]. While restoration of fasting insulin constriction in other vascular beds are unclear, but the
concentration by low-dose infusion did not change the presence of different SSTRs in different vascular struc-
renal vasoconstrictor response to somatostatin, insulin tures and species may explain the selective vasoactive
concentrations in the high postprandial range prevented properties of somatostatin [23–26]. It has been specu-
or mitigated the reduction of GFR and RPF. This was lated that somatostatin interferes with nitric oxide (NO)
independent of preceding or concomitant dosing of insu- production. Recently published results in cirrhotic pa-
lin with somatostatin, indicating a functional antagonism tients suggest an NO-independent mechanism of somato-
in the renal vasculature. statin analogs on forearm blood flow [27], whereas Ro-
High-dose insulin administration, which resulted in driguez-Martin and coworkers showed that l-arginine,
plasma concentrations in the high postprandial range or the precursor of NO production, decreases somatostatin-
as seen in patients with insulin resistance, did not affect like immunoreactivity and the number of specific so-
GFR or RPF over 60 minutes, which is compatible with matostatin receptors in rat pancreatic cells [28], which
some prior investigations [17–20], but not others, which proposes an interaction of somatostatin and NO at least
described a significant increase in RPF and GFR [21, 22]. on this cell type.
These controversial data apply to a rather small effect The hemodynamic actions of somatostatin also might
and were interpreted as the consequence of different be attributed to inhibition of growth hormone and insu-
methods, observation period or to the tested subjects. lin-like growth factor-1 (IGF-1). As expected, a signifi-
Furthermore, insulin resistance and a family history of cant reduction in plasma growth hormone, glucagon and
hypertension were recognized as factors preventing sig- plasma renin activity was detectable. It is possible that
nificant changes in GFR and RPF [21, 22]. However, all this decrease could have contributed to the pharmacody-
of our healthy volunteers were lean, with a normal oral namic effect of somatostatin, but the rapid onset of its
glucose tolerance and there was no association between hemodynamic actions rather suggests direct effects on
a family history of hypertension (N  4) and a lack of vascular smooth muscle cells and/or endothelial cells.
response, as GFR and RPF did not increase in any of Hyperfiltration with increased renal perfusion, in-
our healthy volunteers under study. creased GFR and an increase of kidney size are among
The exact mechanism of somatostatin-induced vaso- the features of early stage of diabetic nephropathy. Mi-
constriction is unclear, yet endothelium-dependent and cropuncture studies showed that diabetic hyperfiltration
independent mechanisms are discussed. Based on the is most likely due to vasodilation of the afferent arteriole.
results of the present study we propose that inhibition Hyperfiltration and increased intraglomerular pressure
of insulin secretion could only play a subtle, if any role play a critical role in the progression of diabetic nephrop-
in this context. RPF and GFR were reduced to a compa- athy and likely contribute to its initiation as well [29, 30].
Significant effort has been made to discern the particularrable degree by somatostatin evidenced by an unchanged
Schmidt et al: Renal hemodynamic effects of somatostatin 1793
accounts for insulin’s vascular effects in humans. J Clin Invest 94:stimulus that leads to glomerular hyperfiltration and sev-
2511–2515, 1994
eral factors have been identified. Among them, hypergly- 13. Schmetterer L, Mu¨ller M, Fasching P, et al: Renal and ocular
cemia per se, growth hormone, glucagon, hyperinsulin- hemodynamic effects of insulin. Diabetes 46:1868–1874, 1997
14. Schnurr E, Lahme W, Ku¨ppers H: Measurement of renal clearanceemia and nitric oxide may contribute to changes in
of inulin and PAH in the steady state without urine collection.
glomerular hemodynamics. There is increasing evidence, Clin Nephrol 13:26–29, 1980
however, that preglomerular vasodilation and hyperfil- 15. DeFronzo RA, Tobin DJ, Andres R: Glucose clamp technique:
A method for quantifying insulin secretion and resistance. Am Jtration may occur via the release of NO. Interestingly
Physiol 237:E214–E223, 1979hyperglycemia [31] as well as hyperinsulinemia [32] are 16. Castellino P, Hunt W, DeFronzo RA: Regulation of renal hemo-
supposed to induce NO release, and an association be- dynamics by plasma amino acid and hormone concentrations. Kid-
ney Int 32(Suppl 22):S15–S20, 1987tween vasodilation on the one hand and hyperglycemia,
17. DeFronzo RA, Cooke CR, Andres R, et al: The effect of insulinhyperinsulinemia and NO is assumed. The connection on renal handling of sodium, potassium, calcium, and phosphate
between NO and glomerular hyperfiltration in early dia- in man. J Clin Invest 55:845–855, 1975
18. Friedberg CE, van Buren M, Bijlsma JA, Koomans HA: Insulinbetes mellitus has been repeatedly shown in experimen-
increases sodium reabsorption in diluting segment in humans: Evi-tal animal studies [33, 34]. dence for indirect mediation through hypokalemia. Kidney Int 40:
In conclusion, we have demonstrated that supplemen- 251–256, 1991
19. Skott P, Vaag A, Bruun NE, et al: Effect of insulin on renaltation of physiological doses of insulin does not influence
sodium handling in hyperinsulinaemic type 2 (non-insulin depen-the renal vasoconstrictive actions of somatostatin. High dent) diabetic patients with peripheral insulin resistance. Diabeto-
circulating insulin concentrations can significantly influ- logia 34:275–281, 1991
20. Stenvinkel P, Bolinder J, Alvestrand A: Effects of insulin onence this reduction in GFR and RPF.
renal haemodynamics and the proximal and distal tubular handling
in healthy subjects. Diabetologia 35:1042–1048, 1992
21. Herlitz H, Widgren B, Urbanavicius V, et al: Stimulatory effectACKNOWLEDGMENTS
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